Skip to main content
OpenTrials

Clinical trial condition

HER2-positive Breast Cancer

Explore clinical trials studying HER2-positive Breast Cancer. Study availability and eligibility vary by location and protocol.

205 public trials 82 recruiting studies
Refine in advanced search Browse all conditions

HER2-positive Breast Cancer trial results

Recruiting

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

NCT04886531

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +7 more
Locations
  • University of Illinois Cancer Center Chicago, Illinois, United States
  • University of Rochester Medical Center Rochester, New York, United States
  • Penn State Cancer Institute Hershey, Pennsylvania, United States
  • University of Wisconsin Madison, Wisconsin, United States
View Trial Details
Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939

Conditions
HER2-positive Breast Cancer
Locations
  • Hospital Provincial del Centenario Rosario, Argentina
  • Monash Health Clayton, Victoria, Australia
  • Barwon Health Geelong, Victoria, Australia
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
View all 186 locations
View Trial Details
Recruiting

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226

Conditions
Adenocarcinoma, Adenocarcinoma of Colon, Breast Diseases, +51 more
Locations
  • The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Birmingham, Alabama, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • The University of Chicago Medicine Comprehensive Cancer Center Chicago, Illinois, United States
  • UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital New Lenox, Illinois, United States
View Trial Details
Recruiting

HER-2 B Cell Peptide Vaccine

NCT06414733

Conditions
Breast Diseases, Breast Neoplasms, Digestive System Diseases, +15 more
Locations
  • Indiana University Melvin & Bren Simon Comprehensive Cancer Center Indianpolis, Indiana, United States
View Trial Details
Recruiting

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

NCT06891833

Conditions
HER2-positive Breast Cancer
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Cancer Hospital Hefei, Anhui, China
  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Hefei, Anhui, China
  • The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing Municipality, China
View all 30 locations
View Trial Details
Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

NCT07102381

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +5 more
Locations
  • Oncology Institute Long Beach, California, United States
  • Cancer & Blood Research Center Los Alamitos, California, United States
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Holy Cross Hospital Fort Lauderdale, Florida, United States
View all 35 locations
View Trial Details
Recruiting

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

NCT07459673

Conditions
Breast Cancer, Breast Cancer Stage IV, Breast Diseases, +6 more
Locations
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details

Related conditions